Decoy Therapeutics Inc. is trading 5.7% down today at $5.75 after disclosing a share resale filing that raised significant dilution concerns.
- The company filed to register up to 808,000 common shares for resale under a committed equity financing facility.
- Market commentary indicates the filing could result in approximately 60% dilution, weighing heavily on the thinly traded pre-clinical biotech stock.